Fifth Third Bancorp Sells 269 Shares of AstraZeneca PLC (NASDAQ:AZN)

Fifth Third Bancorp decreased its position in shares of AstraZeneca PLC (NASDAQ:AZN) by 4.9% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 5,269 shares of the company’s stock after selling 269 shares during the quarter. Fifth Third Bancorp’s holdings in AstraZeneca were worth $387,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors have also recently modified their holdings of the company. Cibc World Markets Corp boosted its position in shares of AstraZeneca by 1.1% during the fourth quarter. Cibc World Markets Corp now owns 12,901 shares of the company’s stock valued at $845,000 after buying an additional 142 shares during the last quarter. CoreCap Advisors LLC boosted its position in shares of AstraZeneca by 31.8% during the fourth quarter. CoreCap Advisors LLC now owns 642 shares of the company’s stock valued at $42,000 after buying an additional 155 shares during the last quarter. Tiller Private Wealth Inc. boosted its position in shares of AstraZeneca by 5.7% during the fourth quarter. Tiller Private Wealth Inc. now owns 3,350 shares of the company’s stock valued at $219,000 after buying an additional 181 shares during the last quarter. Dorsey & Whitney Trust CO LLC boosted its position in shares of AstraZeneca by 0.5% during the fourth quarter. Dorsey & Whitney Trust CO LLC now owns 35,300 shares of the company’s stock valued at $2,313,000 after buying an additional 189 shares during the last quarter. Finally, Pine Valley Investments Ltd Liability Co boosted its position in shares of AstraZeneca by 3.3% during the fourth quarter. Pine Valley Investments Ltd Liability Co now owns 5,995 shares of the company’s stock valued at $393,000 after buying an additional 190 shares during the last quarter. Institutional investors own 20.35% of the company’s stock.

AstraZeneca Stock Down 3.5%

AZN stock opened at $70.97 on Wednesday. The stock’s fifty day simple moving average is $70.07 and its two-hundred day simple moving average is $70.35. The company has a current ratio of 0.90, a quick ratio of 0.70 and a debt-to-equity ratio of 0.65. AstraZeneca PLC has a 1-year low of $61.24 and a 1-year high of $87.68. The stock has a market cap of $220.10 billion, a P/E ratio of 28.50, a P/E/G ratio of 1.35 and a beta of 0.38.

AstraZeneca (NASDAQ:AZN) last posted its quarterly earnings data on Tuesday, April 29th. The company reported $1.24 earnings per share for the quarter, topping the consensus estimate of $1.10 by $0.14. AstraZeneca had a return on equity of 33.14% and a net margin of 14.14%. The business had revenue of $13.59 billion for the quarter, compared to analysts’ expectations of $13.71 billion. During the same quarter in the previous year, the firm earned $2.06 earnings per share. The business’s revenue was up 7.2% on a year-over-year basis. Analysts expect that AstraZeneca PLC will post 4.51 EPS for the current year.

Analysts Set New Price Targets

Separately, BNP Paribas assumed coverage on AstraZeneca in a research report on Tuesday, April 15th. They issued an “outperform” rating and a $75.00 price objective on the stock. One equities research analyst has rated the stock with a hold rating, five have assigned a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat.com, the company has an average rating of “Buy” and an average target price of $85.00.

AstraZeneca Company Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.